The class of drugs including semaglutide (Ozempic, Wegovy) and tirzepatide that produce clinically meaningful weight loss. The essay identifies the current model of lifelong pharmacological weight management as a candidate for correction — not because the drugs don't work, but because the narrative shares structural features with the dietary cholesterol story: a genuine signal overextended into a simplistic model, economically entrenched before long- term data exists
